Patient stories

MRD testing helps patients like you plan and move forward

Multiple myeloma patients discuss their experience with MRD testing

Understand how clonoSEQ® can fit in your multiple myeloma journey


A CLL patient discusses his experience with MRD testing

Understand how clonoSEQ can fit in your CLL journey


If you have multiple myeloma, CLL, B-ALL, or DLBCL, talk with a doctor about tracking your MRD status with clonoSEQ.

Physician Finder

This page is intended for a US-based audience.

clonoSEQ® is an FDA-cleared test used to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT).

clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.